|
| Protocol I phase A | Protocol I phase B | Protocol M | Protocol II phase 1 | Protocol II phase 2 | P |
| Hb (g/L) SR IR |
8.8 (8.2 - 9.1) 9.1 (8.8 - 9.6) |
8.4 (8.1 - 8.9) 8.7 (8.2 - 9.3) |
10.29 ± 0.91 10.6 ± 0.91 |
12.7 ± 1.04 13.0 ± 1.17 |
9.4 (8.3 - 10.2) 9.0 (8.3 - 9.6) |
>0.05 |
| Leukocyte (×109/L) SR IR |
2.67 (1.8 - 3.14) 2.38 (1.5 - 4.5) |
2.10 (1.5 - 2.75) 1.87 (1.3 - 3.0) |
3.05 ± 0.87 3.42 ± 1.09 |
4.61 (3.6 - 6.2) 3.92 (3.2 - 4.9) |
1.78 (1.1 - 2.3) 1.88 (1.1 - 2.3) |
>0.05 |
| ANC (×109/L) SR IR |
0.82 (0.4 - 1.0) 0.84 (0.4 - 1.1) |
0.72 (0.5 - 1.1) 0.89 (0.5 - 1.3) |
1.4 (1.0 - 1.64) 1.68 (1.1 - 2.0) |
2.98 (2.1 - 4.3) 2.5 (1.98 - 3.3) |
0.55 (0.3 - 0.9) 0.69 (0.4 - 1.1) |
>0.05 |
| PLT (×109/L) SR IR |
124.8 (88.2 - 190.8) 117.7 (86.2 - 159.7) |
104.4 (60.2 - 159.2) 123.8 (81.3 - 169.0) |
201.2 ± 80.7 194.8 ± 59.0 |
194.5 (139.4 - 233.7) 163.7 (128.9 183.5) |
157.8 ± 71.4 131.5 ± 84.7 |
>0.05 |
| DND (days) SR IR |
17.9 ± 10.5 18.2 ± 12.8 |
21.5 ± 7.3 20.7 ± 12.0 |
4 (0 - 14) 1 (0 - 5) |
2 (0 - 10) 7 (1 - 11) |
12.2 ± 7.1 11.4 ± 6.0 |
>0.05 |
| FEN (n/%) SR IR |
24 (22%) 20 (22%) |
34 (31%) 30 (32%) |
10 (9%) 4 (4%) |
22 (20%) 20 (22%) |
20 (18%) 18 (19%) |
>0.05 |